Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.

So even after reading all the news about vaccinations, I admit I sneaked into a pharmacy when no one was looking and the fuzz wasn’t around.